Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Published: February 03, 2026 by: CNBC
Sentiment: Positive
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Read More
Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
Published: February 03, 2026 by: Barrons
Sentiment: Negative
Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Published: February 03, 2026 by: CNBC
Sentiment: Neutral
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Read More
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Published: February 03, 2026 by: Reuters
Sentiment: Positive
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Read More
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release.
Read More
Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: (1) to demonstrate PF'3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its e.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.
Read More
Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Negative
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 readouts succeed.
Read More
Novavax Stock Pops After Pfizer Licensing Agreement
Published: January 20, 2026 by: Schaeffers Research
Sentiment: Positive
Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.
Read More
Which Pharma Stock Stands Taller Right Now: LLY or PFE?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.
Read More
MoneyShow's Best Investment Ideas For 2026: Part 7
Published: January 19, 2026 by: Seeking Alpha
Sentiment: Neutral
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.
Read More
What to Expect From Pfizer's Non-Oncology Business in Q4?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
Read More
Pfizer: Rebound Has Just Started
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.
Read More
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
These 3 Stocks Trade at Discounts the Market Won't Ignore Forever
Published: January 05, 2026 by: MarketBeat
Sentiment: Positive
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is still the strongest market trend entering 2026, and the usual suspects like NVIDIA Corp. NASDAQ: NVDA and Alphabet Inc. NASDAQ: GOOGL are up once again on the first day of trading.
Read More
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Published: January 05, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
Read More
Pfizer 2026: The Reset Year
Published: January 02, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion.
Read More
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter.
Read More
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
Published: December 31, 2025 by: MarketBeat
Sentiment: Negative
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.
Read More
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
Published: December 31, 2025 by: Invezz
Sentiment: Positive
Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income.
Read More
Jim Cramer Names His Favorite Dividend Stocks
Published: December 29, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
3 Under-The-Radar Dividend Stocks to Buy on the Cheap
Published: December 24, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Dividend stocks have been under pressure in the past few years due to the broader economy's unpredictable swings.
Read More
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000